Verition Fund Management’s Travere Therapeutics TVTX Stock Holding History

Verition Fund Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	+25,300	New	+$1.12M	0.01%	1270
2026 Q1	–	Sell	-56,010	Closed	-$2.14M	–	3554
2025 Q4	$2.14M	Buy	+56,010	New	+$1.82M	0.01%	1546
2025 Q2	–	Sell	-73,454	Closed	-$1.32M	–	3875
2025 Q1	$1.32M	Sell	73,454 -2,854	-4%	-$57.9K	0.01%	1905
2024 Q4	$1.33M	Buy	76,308 +15,437	+25%	+$273K	0.01%	1846
2024 Q3	$852K	Buy	60,871 +32,583	+115%	+$339K	﹤0.01%	1993
2024 Q2	$233K	Buy	+28,288	New	+$191K	﹤0.01%	2505
2023 Q3	–	Sell	-10,050	Closed	-$154K	–	2688
2023 Q2	$154K	Buy	+10,050	New	+$183K	﹤0.01%	1913

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's TVTX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 25,300 shares worth $1.44M. The stake represents 0.01% of the portfolio and ranks #1270 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in TVTX as recently as Q4 2025.

Verition Fund Management first reported a position in TVTX in Q2 2023 and has held it in 7 quarters since. The position peaked at $2.14M in Q4 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Verition Fund Management held 25,300 shares of Travere Therapeutics worth $1.44M as of Q2 2026.
Travere Therapeutics was a new Verition Fund Management position in Q2 2026.
Travere Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1270 holding.
Verition Fund Management first reported a position in Travere Therapeutics in Q2 2023 and has held it in 7 quarters since.
Verition Fund Management's Travere Therapeutics position peaked at $2.14M in Q4 2025.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.